New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
08:13 EDTMACKMerrimack MM-141 preclinical study published in Molecular Cancer Therapeutics
Merrimack Pharmaceuticals announced that the manuscript "MM-141, an IGF-1R- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-1R Inhibitors" has been published in Molecular Cancer Therapeutics and selected for the Highlights section in the current issue . This publication describes the preclinical development of Merrimack's MM-141, a novel bispecific tetravalent antibody that binds to IGF-1R and ErbB3 receptors. With this mechanism, MM-141 is able to inhibit oncogenic signaling through the PI3K/AKT/mTOR pathway, which is a driving force behind cell growth. MM-141 recently completed the monotherapy portion of a Phase 1 study in the United States and Europe. It is currently being investigated in a Phase 1 combination study and is expected to enter Phase 2 development in 2014. IGF-1R, the receptor activated by insulin-like growth factor 1, has the ability to induce cellular growth and proliferation. Thus, it has been implicated in promoting resistance to both chemotherapies and targeted therapies. However, the effectiveness of current IGF-1R inhibitors in the clinic has been limited, as cancer cells have the ability to develop resistance to therapies by signaling through alternative pathways. Through a systems biology-based methodology, Merrimack researchers have found that cancer cells can develop resistance to IGF-1R that is mediated through ErbB3. Therefore, dual inhibition of IGF-1R and ErbB3 pathways would be necessary to block the PI3K/AKT/mTOR pathway, resulting in the arrest of tumor cell growth. In preclinical in vitro and in vivo models, MM-141 was more active than a combination of anti-ErbB3 and anti-IGF-1R monoclonal antibodies. MM-141 was able to inhibit PI3K/AKT/mTOR signaling and potentiated the activity of cytotoxic and targeted therapies, supporting its ongoing clinical development.
News For MACK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
11:09 EDTMACKMerrimack management to meet with Jefferies
Subscribe for More Information
May 13, 2015
10:02 EDTMACKOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A.O. Smith (AOS) initiated with a Hold at Gabelli... Bellicum Pharmaceuticals (BLCM) initiated with a Neutral at Guggenheim... Criteo (CRTO) initiated with a Hold at Evercore ISI... FleetCor (FLT) initiated with a Buy at Monness Crespi... Franco-Nevada (FNV) initiated with a Buy at Canaccord... Horizon Technology (HRZN) initiated with an Outperform at Oppenheimer... Merrimack (MACK) initiated with a Buy at Guggenheim... Mobileye (MBLY) initiated with a Sector Weight at Pacific Crest... Monroe Capital (MRCC) initiated with an Outperform at Oppenheimer... Royal Gold (RGLD) initiated with a Hold at Canaccord... Silver Wheaton (SLW) initiated with a Buy at Canaccord... U.S. Concrete (USCR) initiated with a Buy at Stifel... Ziopharm (ZIOP) initiated with a Neutral at Guggenheim.
09:11 EDTMACKMerrimack has a conference call hosted by JPMorgan
JPMorgan Analyst Rama will host a conference call with CEO Bob Mulroy on May 15 at 10 am.
06:30 EDTMACKMerrimack initiated with a Buy at Guggenheim
Target $15.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use